Galloway Capital Partners Announces Investment in WW International and Believes Shares Are Worth Multiples of Current Price
WW International, Inc. (WW) Q1 2026 Earnings Call Transcript
WW International Q1 Earnings Call Highlights
WW International Logs Lower Sales
Weight Watchers Announces First Quarter 2026 Results
Weight Watchers Expands Med+ With Access to New Ozempic® pill (semaglutide)
Is Eli Lilly (LLY) 34.7% Undervalued After Q1 2026 Beat? EPS $8.26 vs. $7.02 Est.; Revenue $19.80B vs. $17.62B Est.; GF Score 94/100
Weight Watchers Announces Actions to Utilize Up to $40 million to Pay Down Debt
Weight Watchers Schedules First Quarter 2026 Earnings Conference Call
Weight Watchers Appoints Proven Healthcare Executive Heather Thiltgen to Board of Directors
Weight Watchers Appoints Proven Healthcare Executive Heather Thiltgen to Board of Directors
Weight Watchers Launches Eli Lilly and Company’s New Oral GLP-1 Foundayo® Available Through LillyDirect
Weight Watchers Announces Board Committee Appointments
Weight Watchers Appoints Lisa Gavales and Sue Gove to Board of Directors
Weight Watchers Announces Leadership Transition and Board Updates
Weight Watchers Announces Best in Market Self-Pay Wegovy® Pricing for Med+ Members and the Launch of Preferred Subscription Pricing for Wegovy via NovoCare®
WW International, Inc. (WGHTQ) Q4 2025 Earnings Call Transcript
WW International beats fourth quarter estimates on clinical subscription growth
Weight Watchers Announces Fourth Quarter and Full Year 2025 Results
WW International, Inc. (NASDAQ:WW) Short Interest Up 28.9% in February
Weight Watchers Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call
Weight Watchers Partners with PVOLVE to Deliver Clinically Validated Strength Workouts to Members in the GLP-1 Era
Weight Watchers Expands Its Integrated GLP-1 Platform with Access to Wegovy® Pill Advancing a New Standard for Long-Term Weight Health
WW International (NASDAQ:WW) Share Price Passes Above 200-Day Moving Average – Here’s What Happened
Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era
Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era
Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era
Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era
WW International: First Normal Quarter Shows Signs Of Stability
WeightWatchers to sell Novo Nordisk's Wegovy pill after 2026 launch
WW International, Inc. (WW) Q3 2025 Earnings Call Transcript
WeightWatchers Announces Third Quarter 2025 Results
WeightWatchers International shares climb after partnership with Amazon Pharmacy
WeightWatchers to offer faster delivery of weight loss drugs through new partnership with Amazon Pharmacy
WeightWatchers Collaborates With Amazon Pharmacy to Increase Medication Delivery Speed, Convenience and Savings For Members
WeightWatchers Launches RxFlexFund™, a New Employer Model for Expanding GLP-1 Coverage
WeightWatchers for Business Annual Report Shows Breakthrough Weight Loss Results and Health Outcomes
2 Stocks in Focus as New Analyst Initiates Coverage
Queen Latifah Named Spokeswoman as WeightWatchers Launches First Comprehensive Menopause Programme
Queen Latifah Named Spokeswoman as WeightWatchers Launches First Comprehensive Menopause Program
WeightWatchers Advances International Growth With Strategic Leadership Appointment
WW International, Inc. (WW) Q2 2025 Earnings Call Transcript
WeightWatchers Announces Second Quarter 2025 Results
WeightWatchers Appoints SoulCycle Co-Founder Julie Rice as Chief Experience Officer to Lead Community and Brand Innovation
WeightWatchers Reschedules Second Quarter 2025 Earnings Release and Conference Call to Finalize Fresh Start Accounting Adoption in Connection with Emergence
WeightWatchers Schedules Second Quarter 2025 Earnings Conference Call
WeightWatchers reboots with focus on medical weight-loss and menopause care
WeightWatchers to exit process to cut $1.15 billion debt next week
CheqUp and WeightWatchers Announce Strategic Partnership to Support Growing Use of GLP-1 Medications in the UK
Wellness companies eager to avoid WeightWatchers' fate embrace weight-loss drugs